['Type 2 diabetes (T2DM) is closely associated with the development of heart failure, which might be related with impaired substrate metabolism and accumulation of myocardial lipids (MYCL). The aim of this study was to investigate the impact of an acute pharmacological inhibition of adipose tissue lipolysis leading to reduced availability of circulating FFA on MYCL and heart function in T2DM.', '8 patients with T2DM (Age: 56\xa0±\xa011; BMI: 28\xa0±\xa03.5\xa0kg/m(2); HbA1c: 7.29\xa0±\xa00.88%) were investigated on two study days in random order. Following administration of Acipimox or Placebo MYCL and heart function were measured by (1)H-magnetic-resonance-spectroscopy and tomography at baseline, at 2 and at 6\xa0h. Acipimox reduced circulating FFA by -69% (p\xa0<\xa00.001), MYCL by -39\xa0±\xa041% (p\xa0<\xa00.001) as well as systolic heart function (Ejection Fraction (EF): -13\xa0±\xa08%, p\xa0=\xa00.025; Cardiac Index: -16\xa0±\xa015%, p\xa0=\xa00.063 compared to baseline). Changes in plasma FFA concentrations strongly correlated with changes in MYCL (r\xa0=\xa00.707; p\xa0=\xa00.002) and EF (r\xa0=\xa00.651; p\xa0=\xa00.006). Diastolic heart function remained unchanged.'] Does suppression of plasma free fatty acids reduce myocardial lipid content and systolic function in type 2 diabetes?